Courage Therapeutics, a company developing novel treatments for genetic and dietary obesity and diseases of wasting, announced it has closed funding led by Arsenal Bridge Ventures, a venture capital firm specializing in high-impact, early-stage biotech companies, and joined by existing investors. This brings the company's funding to over $11M.